Kawasaki Disease
2008; Lippincott Williams & Wilkins; Volume: 118; Issue: 7 Linguagem: Indonésio
10.1161/circulationaha.107.751404
ISSN1524-4539
AutoresAnnette Baker, Jane W. Newburger,
Tópico(s)Cardiac Structural Anomalies and Repair
ResumoHomeCirculationVol. 118, No. 7Kawasaki Disease Free AccessReview ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessReview ArticlePDF/EPUBKawasaki Disease Annette L. Baker, RN, MSN, PNP and Jane W. Newburger, MD, MPH Annette L. BakerAnnette L. Baker From the Department of Cardiology (A.L.B., J.W.N.), Children's Hospital, Boston, Mass, and the Department of Pediatrics (J.W.N.), Harvard Medical School, Boston, Mass. and Jane W. NewburgerJane W. Newburger From the Department of Cardiology (A.L.B., J.W.N.), Children's Hospital, Boston, Mass, and the Department of Pediatrics (J.W.N.), Harvard Medical School, Boston, Mass. Originally published12 Aug 2008https://doi.org/10.1161/CIRCULATIONAHA.107.751404Circulation. 2008;118:e110–e112Kawasaki disease is an acute childhood illness that is characterized by inflammation of the blood vessels. Early diagnosis and treatment are important to prevent possible damage to the coronary arteries, which supply oxygen to the heart muscle.The classic symptoms of Kawasaki disease are listed below: Fever lasting for at least 4 daysRed eyes (conjunctivitis), usually without drainageRedness of the lips, throat, and tongue (strawberry tongue)Redness and swelling of the hands and feet, followed later by peeling of skin on the fingers and toesA rashSwollen gland in the neck (usually 1 large) measuring at least 1.5 cm or largerAlthough children with Kawasaki disease usually have fever plus 4 of the 5 signs listed above, some children have fewer symptoms (incomplete Kawasaki disease). If your child has a fever for 5 or more days with 2 or 3 of these classic symptoms, without another diagnosis, you should bring your child to the doctor or other healthcare provider. In addition to the signs listed above, children with Kawasaki disease are often very fussy or irritable. Vomiting, diarrhea, abdominal pain, respiratory symptoms such as cough, and joint pains are common in the days before diagnosis.What Heart Problems Can Occur in Kawasaki Disease?Inflammation in the walls of the coronary arteries can cause them to weaken. The weakened artery forms an aneurysm, which is a bubble-shaped (saccular) or cigar-shaped (fusiform) enlargement (Figure). Without timely treatment, 1 in 5 children with Kawasaki disease will develop coronary aneurysms. Treatment in the first 10 days of illness reduces the risk of aneurysm formation to less than 5%. Kawasaki disease can also cause inflammation of the heart muscle (myocarditis) and leakiness of heart valves, but these problems are almost always temporary. Download figureDownload PowerPointFigure. Coronary arteries are demonstrated in red. The panel on the left shows a heart with normal coronary arteries, and the panel on the right shows a heart with large aneurysms of 2 types: fusiform (cigar shaped) and saccular (bubble shaped).What Causes Kawasaki Disease?The cause of Kawasaki disease is unknown. Kawasaki disease is not spread from person to person. Many experts think that Kawasaki disease is an immune reaction triggered by an infection.Who Is at Risk?Although the risk is highest in those of Japanese origin, children of all races and ethnic groups can develop Kawasaki disease. Most children are younger than age 5 years, but even older children and teenagers can be affected. The risk of developing coronary artery aneurysms is greatest for children (1) who are younger than age 6 months, (2) whose diagnosis and treatment are delayed, or (3) who continue to have fever despite treatment.What Is the Typical Course of Kawasaki Disease?The symptoms of Kawasaki disease usually resolve within 4 to 6 weeks, but return of your child's usual personality and energy level may take as long as 8 weeks.How Is Kawasaki Disease Treated?Kawasaki disease is treated with intravenous immunoglobulin (IVIG), given through an intravenous line in the hospital over 8 to 12 hours. For most patients, IVIG improves fever and lowers the risk of coronary aneurysms if administered in the first 10 days, and ideally within 7 days, of the start of fever. Aspirin also is prescribed in high doses to control fever. Once the fever is gone, the aspirin dose is lowered to a single daily dose to prevent blood from clotting in the coronary arteries. If no aneurysms are present by 5 or 6 weeks after the onset of fever, aspirin is stopped. Children with persistent fever or worsening aneurysms despite IVIG therapy are often treated with more IVIG infusions and/or other therapies to lessen inflammation. For children who have developed coronary aneurysms, treatment is aimed at preventing blood clots in the coronary arteries. Aneurysms usually reach their biggest size about 4 weeks after the onset of fever. Depending on the size of the aneurysms, children may be treated with at least 1 of the following medications: low-dose aspirin, clopidogrel (Plavix), warfarin (Coumadin), or low-molecular-weight heparin (Lovenox). Such treatments are continued long-term. Some patients with very large aneurysms or those who have had heart attacks may need additional medicines.What Happens to Coronary Aneurysms?Half of aneurysms heal to a normal size after 1 to 2 years, although healing may cause the wall of the artery to become thicker than usual. The smaller the initial size of the aneurysm, the more likely it is to heal to its normal size.Over years, blockage (stenoses) may develop in damaged coronary arteries, usually at either end of an aneurysm. Children with the largest aneurysms are the most likely to develop coronary artery stenoses. If the heart muscle does not receive enough oxygen (for example, because blood flow through a coronary artery is impaired by stenosis or by a blood clot), heart pain (angina) or a heart attack may occur. New blood vessels (collaterals) often grow to supplement the blood supply to the heart muscle territory serviced by a gradually blocking coronary artery.How Are Children Followed Up After Kawasaki Disease?In the first 6 weeks of the illness, children usually have blood tests and an echocardiogram on a minimum of 3 occasions: at the time of diagnosis and then 1 to 2 weeks and 4 to 6 weeks after treatment. Children with persistent fever or coronary aneurysms may have additional testing.After 6 weeks, the frequency of follow-up visits depends on whether your child has coronary aneurysms, and, if so, how large the aneurysms are. All children who have had Kawasaki disease should adopt a heart-healthy lifestyle (that is, no smoking, regular exercise, heart-healthy diet) and, if needed, be treated for risk factors for adult-type coronary artery disease, such as high blood pressure and high cholesterol. Children in whom coronary enlargement was never detected return for follow-up infrequently.Follow-Up Testing for Children With AneurysmsThe types of testing for children with aneurysms are as follows: Electrocardiogram: Records electrical activity in the heart.Echocardiogram: Ultrasound of the heart to image coronary arteries, as well as heart muscle and heart valve function.Cardiac magnetic resonance imaging or computed tomography angiography: Shows shape and size of the coronary arteries when they cannot be well seen by echocardiography (for example, in older children).Stress tests with myocardial imaging: Depending on the age of your child, stress testing may be done by use of a medication (babies and children under age 5 years) or by exercise (in older children). The response of the heart to stress may be assessed by echocardiogram, cardiac magnetic resonance imaging, or nuclear imaging.Heart catheterization (coronary angiography): A tube is threaded through a leg artery to the heart, and pictures are taken of the coronary arteries to show their size and shape.What Can Be Done if a Coronary Blockage Is Found?If coronary artery blockage is found at cardiac catheterization, it may be opened with use of a balloon or a tube placed inside the vessel (stent). Coronary blockages in some patients are better treated with coronary artery bypass surgery. The majority of children return to normal lives after bypass graft surgery for Kawasaki disease.SummaryKawasaki disease is an illness with potentially serious effects on the heart. Current therapy is focused on the early treatment and close monitoring of cardiac status. Children who never developed aneurysms (that is, whose coronary arteries were always normal) have a rate of heart problems similar to that found in the general population; research studies are exploring whether arteries in these children might be slightly stiffer or thicker than usual. Most children with coronary aneurysms take part in normal activities but need to see their cardiologist regularly. These children/adults may have some activity restrictions depending on the size of their aneurysms and whether or not they are on medicines that slow blood clotting. All children who have had Kawasaki disease should maintain a heart-healthy lifestyle and reduce risk factors for hardening of the arteries (atherosclerosis), such as high cholesterol, high blood pressure, or smoking.The information contained in this Circulation Cardiology Patient Page is not a substitute for medical advice, and the American Heart Association recommends consultation with your doctor or healthcare professional.Sources of FundingKawasaki disease education is supported in part by the Ciaranello Family Fund.DisclosuresNone.FootnotesCorrespondence to Jane W. Newburger, MD, MPH, Professor of Pediatrics, Harvard Medical School, Associate Chief for Academic Affairs, Department of Cardiology, Children's Hospital Boston, 300 Longwood Ave, Boston, MA 02115. E-mail [email protected]Additional ResourcesNewburger JW, MPH, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, Shulman ST, Bolger AF, Ferrieri P, Baltimore RS, Wilson WR, Baddour LM, Levison ME, Pallasch TJ, Falace DA, Taubert KA. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Available at: http://circ.ahajournals.org/cgi/content/full/110/17/2747.Google ScholarKawasaki Disease Foundation Web site. Available at: http://www.kdfoundation.org/.Google ScholarCenters for Disease Control and Prevention. Kawasaki syndrome. Available at: http://www.cdc.gov/kawasaki/index.html.Google Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By León-Lara X, Vargas-Castillo A, Ávila-Nava A, Guevara-Cruz M, Serralde Zúñiga A and Medina-Vera I (2021) Hypothesis regarding the connections between severe COVID-19 in children and nutrition: a narrative review, Nutrición Hospitalaria, 10.20960/nh.03452, . Del Principe D, Pietraforte D, Gambardella L, Marchesi A, Tarissi de Jacobis I, Villani A, Malorni W and Straface E (2017) Pathogenetic determinants in Kawasaki disease: the haematological point of view, Journal of Cellular and Molecular Medicine, 10.1111/jcmm.12992, 21:4, (632-639), Online publication date: 1-Apr-2017. Telcharova-Mihaylovska A, Nikolova I, Marinov R, Stefanov S, Gaidarova M, Ganeva M and Temelkova K (2017) Kawasaki disease – experience of Pediatric University Hospital, Sofia, Bulgaria, 1993–2014. Part II: cardiovascular manifestations and treatment, Biotechnology & Biotechnological Equipment, 10.1080/13102818.2017.1347522, 31:5, (974-978), Online publication date: 3-Sep-2017. Kawamura I, Komiyama K, Fukamizu S, Shibui T, Ashikaga T and Sakurada H (2017) Combination of drug-coated balloon angioplasty and excimer laser coronary angioplasty ablation for coronary restenosis of Kawasaki disease: A case report, Journal of Cardiology Cases, 10.1016/j.jccase.2016.09.002, 15:1, (18-21), Online publication date: 1-Jan-2017. Bastami M, Nariman-Saleh-Fam Z, Saadatian Z, Nariman-Saleh-Fam L, Omrani M, Ghaderian S and Masotti A (2016) The miRNA targetome of coronary artery disease is perturbed by functional polymorphisms identified and prioritized by in-depth bioinformatics analyses exploiting genome-wide association studies, Gene, 10.1016/j.gene.2016.08.054, 594:1, (74-81), Online publication date: 1-Dec-2016. Ye Q, Gong F, Shang S and Hu J (2016) Intravenous immunoglobulin treatment responsiveness depends on the degree of CD8 + T cell activation in Kawasaki disease, Clinical Immunology, 10.1016/j.clim.2016.08.012, 171, (25-31), Online publication date: 1-Oct-2016. Yoshikane Y, Koga M, Imanaka-Yoshida K, Cho T, Yamamoto Y, Yoshida T, Hashimoto J, Hirose S and Yoshimura K (2015) JNK is critical for the development of Candida albicans-induced vascular lesions in a mouse model of Kawasaki Disease, Cardiovascular Pathology, 10.1016/j.carpath.2014.08.005, 24:1, (33-40), Online publication date: 1-Jan-2015. Ye Q, Shao W, Shang S, Zhang T, Hu J and Zhang C (2015) A Comprehensive Assessment of the Value of Laboratory Indices in Diagnosing Kawasaki Disease, Arthritis & Rheumatology, 10.1002/art.39112, 67:7, (1943-1950), Online publication date: 1-Jul-2015. Pietraforte D, Gambardella L, Marchesi A, de Jacobis I, Viora M, Del Principe D, Villani A, Malorni W and Straface E (2015) Red blood cells as bioindicators of cardiovascular risk in Kawasaki disease: A case report, International Journal of Cardiology, 10.1016/j.ijcard.2014.11.223, 181, (311-313), Online publication date: 1-Feb-2015. Ye Q, Shao W, Shang S and Zhou M (2015) Value of the N-terminal of prohormone brain natriuretic peptide in diagnosis of Kawasaki disease, International Journal of Cardiology, 10.1016/j.ijcard.2014.10.095, 178, (5-7), Online publication date: 1-Jan-2015. Taddio A, Pellegrin M, Centenari C, Filippeschi I, Ventura A and Maggiore G (2012) Acute Febrile Cholestatic Jaundice in Children, Journal of Pediatric Gastroenterology & Nutrition, 10.1097/MPG.0b013e31825513de, 55:4, (380-383), Online publication date: 1-Oct-2012. Straface E, Marchesi A, Gambardella L, Metere A, Tarissi de Jacobis I, Viora M, Giordani L, Villani A, Del Principe D, Malorni W and Pietraforte D (2012) Does Oxidative Stress Play a Critical Role in Cardiovascular Complications of Kawasaki Disease?, Antioxidants & Redox Signaling, 10.1089/ars.2012.4660, 17:10, (1441-1446), Online publication date: 15-Nov-2012. Fennelly G, Rosenberg M, Crain E and Coyle C (2010) Infectious disease emergencies Clinical Manual of Emergency Pediatrics, 10.1017/CBO9780511919268.015, (362-432) Boivin W, Cooper D, Hiebert P and Granville D (2009) Intracellular versus extracellular granzyme B in immunity and disease: challenging the dogma, Laboratory Investigation, 10.1038/labinvest.2009.91, 89:11, (1195-1220), Online publication date: 1-Nov-2009. Castro P, Urbano L and Costa I (2009) Doença de Kawasaki, Anais Brasileiros de Dermatologia, 10.1590/S0365-05962009000400002, 84:4, (317-329), Online publication date: 1-Aug-2009. August 12, 2008Vol 118, Issue 7 Advertisement Article InformationMetrics https://doi.org/10.1161/CIRCULATIONAHA.107.751404PMID: 18695195 Originally publishedAugust 12, 2008 PDF download Advertisement SubjectsCongenital Heart DiseaseCoronary CirculationEpidemiologyTreatmentVascular Biology
Referência(s)